SC
CRL icon

Swan Capital’s Charles River Laboratories CRL Stock Holding History

Swan Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.06K Hold
47
– – ﹤0.01% 221
2025
Q4 		$9.33K Hold
47
– – ﹤0.01% 179
2025
Q3 		$7.32K Hold
47
– – ﹤0.01% 183
2025
Q2 		$7.09K Hold
47
– – ﹤0.01% 193
2025
Q1 		$7.04K Hold
47
– – ﹤0.01% 169
2024
Q4 		$8.63K Hold
47
– – ﹤0.01% 140
2024
Q3 		$9.21K Hold
47
– – ﹤0.01% 143
2024
Q2 		$9.66K Buy
+47
New +$10.7K 0.01% 130

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Swan Capital's CRL Position: Q1 2026 in Review

Swan Capital held its Charles River Laboratories (CRL) position steady in Q1 2026 at 47 shares worth $8.06K. The position accounts for ﹤0.01% of the portfolio, ranked #221.

Swan Capital first reported a position in CRL in Q2 2024 and has held it in 8 quarters since. The position peaked at $9.66K in Q2 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Swan Capital held 47 shares of Charles River Laboratories worth $8.06K as of Q1 2026.
  • Swan Capital left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Swan Capital's portfolio in Q1 2026, its #221 holding.
  • Swan Capital first reported a position in Charles River Laboratories in Q2 2024 and has held it in 8 quarters since.
  • Swan Capital's Charles River Laboratories position peaked at $9.66K in Q2 2024.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.